The additional facet of immunoscore: Immunoprofiling as a possible predictive tool for cancer treatment

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Ascierto, Paolo A ^a   Capone, Mariaelena ^a   Urba, Walter J ^b   Bifulco, Carlo B ^b   Botti, Gerardo ^a   Lugli, Alessandro ^c   Marincola, Francesco M ^d   Ciliberto, Gennaro ^a   Galon, Jérôme ^e,f,g   Fox, Bernard A ^b,h  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b EARLE A CHILES RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^e INSERM   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g CENTRE DE RECHERCHE DES CORDELIERS   (France)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Immunoprofiling; Immunotherapy; Ipilimumab; Tumor microenvironment; Tumor infiltrating lymphocytes

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; INDOLEAMINE 2,3 DIOXYGENASE; IPILIMUMAB; NIVOLUMAB; TRANSCRIPTION FACTOR FOXP3; URELUMAB;

ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; GENE EXPRESSION REGULATION; HUMAN; IMMUNODETECTION; IMMUNOLOGICAL PROCEDURES; IMMUNOMODULATION; IMMUNOSCORE; INDOLEAMINE 2,3 DIOXYGENASE GENE; INTERMETHOD COMPARISON; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; OVERALL SURVIVAL; TRANSCRIPTION FACTOR FOXP3 GENE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GENE; TUMOR MICROENVIRONMENT;

HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROGNOSIS;

EID: 84874397303     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-54     Document Type: Editorial

References (18)

1. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012, 10:1. 10.1186/1479-5876-10-1, 3269368, 22214470.
2. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964. 10.1126/science.1129139, 17008531.
3. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, Galon J. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011, 29:610-618. 10.1200/JCO.2010.30.5425, 21245428.
4. Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009, 27:5944-5951. 10.1200/JCO.2008.19.6147, 19858404.
5. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012, 12:298-306. 10.1038/nrc3245, 22419253.
6. Eiró N, Pidal I, Fernandez-Garcia B, Junquera S, Lamelas ML, Del Casar JM, González LO, López-Muñiz A, Vizoso FJ. Impact of CD68/(CD3 + CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer. PLoS One 2012, 7:e52796. 10.1371/journal.pone.0052796, 3530508, 23300781.
7. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011, 1:54-67. 10.1158/2159-8274.CD-10-0028, 3203524, 22039576.
8. Cochran AJ, Wen D-R, Farzad Z, Stene MA, McBride W, Lana AM, Hoon DS, Morton DL. Immune suppression by melanoma cells as a factor in the generation of metastatic disease. Anticancer Res 1989, 9:859-864.
9. Cochran AJ, Morton DL, Stern S, Lana AM, Essner R, Wen DR. Sentinel lymph nodes show profound Downregulation of antigen-presenting cells of the Paracortex: implications for tumor biology and treatment. Mod Pathol 2001, 14:604-608. 10.1038/modpathol.3880358, 11406663.
10. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723. 10.1056/NEJMoa1003466, 3549297, 20525992.
11. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010, 37:508-516. 10.1053/j.seminoncol.2010.09.008, 21074066.
12. Kline J, Gajewski TF. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs 2011, 11:1354-1359.
13. Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD. Science gone translational: the OX40 agonist story. Immunol Rev 2011, 244:218-231. 10.1111/j.1600-065X.2011.01069.x, 22017441.
14. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gómez H, Bastholt L, Chasalow SD, Berman D. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011, 9:204. 10.1186/1479-5876-9-204, 3239318, 22123319.
15. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454. 10.1056/NEJMoa1200690, 3544539, 22658127.
16. Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 2013, in press).
17. Coppola D, Nebozhyn M, Khalil F, Dai H, Yeatman T, Loboda A, Mulé JJ. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol 2011, 179:37-45. 10.1016/j.ajpath.2011.03.007, 3123872, 21703392.
18. Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?. Sci Rep 2012, 2:765. 3479449, 23097687.